MXPA03010705A - Formulaciones farmaceuticas solidas que comprenden modafinil. - Google Patents

Formulaciones farmaceuticas solidas que comprenden modafinil.

Info

Publication number
MXPA03010705A
MXPA03010705A MXPA03010705A MXPA03010705A MXPA03010705A MX PA03010705 A MXPA03010705 A MX PA03010705A MX PA03010705 A MXPA03010705 A MX PA03010705A MX PA03010705 A MXPA03010705 A MX PA03010705A MX PA03010705 A MXPA03010705 A MX PA03010705A
Authority
MX
Mexico
Prior art keywords
modafinil
pharmaceutical formulations
solid pharmaceutical
compositions
disintegrants
Prior art date
Application number
MXPA03010705A
Other languages
English (en)
Inventor
Vincent Corvari
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26852708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03010705(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MXPA03010705A publication Critical patent/MXPA03010705A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invencion se refiere a composiciones de modafinil, incluyendo composiciones de modafinil y uno o mas diluyentes, desintegrantes, aglutinantes y lubricantes, y a los procesos para su preparacion.
MXPA03010705A 2001-05-25 2002-05-23 Formulaciones farmaceuticas solidas que comprenden modafinil. MXPA03010705A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29369501P 2001-05-25 2001-05-25
US10/155,913 US7297346B2 (en) 2001-05-25 2002-05-23 Pharmaceutical formulations of modafinil
PCT/US2002/016369 WO2002096401A1 (en) 2001-05-25 2002-05-24 Solid pharmaceutical formulations comprising modafinil

Publications (1)

Publication Number Publication Date
MXPA03010705A true MXPA03010705A (es) 2004-05-27

Family

ID=26852708

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010705A MXPA03010705A (es) 2001-05-25 2002-05-23 Formulaciones farmaceuticas solidas que comprenden modafinil.

Country Status (20)

Country Link
US (1) US7297346B2 (es)
EP (1) EP1397127B8 (es)
JP (1) JP4443119B2 (es)
KR (1) KR100911779B1 (es)
CN (1) CN1318026C (es)
AT (1) ATE357228T1 (es)
AU (1) AU2002318155B8 (es)
BR (1) BRPI0210085B8 (es)
CA (1) CA2448456C (es)
DE (1) DE60219005T2 (es)
ES (1) ES2281527T3 (es)
HK (1) HK1061652A1 (es)
IL (1) IL158959A (es)
MX (1) MXPA03010705A (es)
MY (1) MY129376A (es)
NO (1) NO328805B1 (es)
NZ (1) NZ530040A (es)
TW (1) TWI321475B (es)
WO (1) WO2002096401A1 (es)
ZA (1) ZA200309978B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010125A1 (en) 2000-07-27 2002-02-07 Teva Pharmaceutical Industries Ltd. Crystalline and pure modafinil, and process of preparing the same
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
WO2004010979A1 (en) * 2002-07-25 2004-02-05 Ranbaxy Laboratories Limited Processes for the preparation of oral dosage formulations of modafinil
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
CA2420180A1 (en) * 2003-02-28 2004-08-28 Bernard Charles Sherman Tablets comprising modafinil
CA2519117C (en) * 2003-03-17 2010-03-02 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
CN101031290B (zh) * 2003-09-18 2011-09-21 赛福伦公司 改良释放的莫达非尼药物组合物
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
BRPI0612440A2 (pt) * 2005-04-08 2010-11-23 New River Pharmaceuticals Inc composição farmacêutica e uso de um profármaco de anfetamina
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
KR101431711B1 (ko) * 2008-05-07 2014-08-21 삼성전자 주식회사 발광 장치 및 발광 시스템의 제조 방법, 상기 방법을이용하여 제조한 발광 장치 및 발광 시스템
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
HUE037616T2 (hu) 2010-12-08 2018-09-28 Codexis Inc Biokatalizátorok és eljárások armodafinil szintéziséhez
CN103338742A (zh) * 2010-12-21 2013-10-02 阿克佐诺贝尔化学国际公司 用于含水化妆品和药物应用的速溶粉末
FR2987266B1 (fr) 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1570994A (en) * 1923-11-20 1926-01-26 William A Cook Spring-forming die
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
GB9225492D0 (en) * 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2702968B1 (fr) * 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
FR2706767B1 (es) * 1993-06-22 1995-09-08 Lafon Labor
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
CN1277550A (zh) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
IL143407A0 (en) * 1998-12-18 2002-04-21 Abbott Lab Controlled release formulation of divalproex sodium
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6670358B2 (en) * 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides

Also Published As

Publication number Publication date
TWI321475B (en) 2010-03-11
JP4443119B2 (ja) 2010-03-31
DE60219005D1 (de) 2007-05-03
AU2002318155B2 (en) 2007-03-01
KR100911779B1 (ko) 2009-08-12
US7297346B2 (en) 2007-11-20
DE60219005T2 (de) 2007-12-13
EP1397127A1 (en) 2004-03-17
IL158959A0 (en) 2004-05-12
KR20040005986A (ko) 2004-01-16
IL158959A (en) 2010-06-30
EP1397127B8 (en) 2008-02-20
ES2281527T3 (es) 2007-10-01
BRPI0210085A (pt) 2004-06-29
ZA200309978B (en) 2005-05-25
CA2448456A1 (en) 2002-12-05
MY129376A (en) 2007-03-30
BRPI0210085B1 (pt) 2020-11-10
CA2448456C (en) 2010-07-27
CN1511031A (zh) 2004-07-07
ATE357228T1 (de) 2007-04-15
US20030022940A1 (en) 2003-01-30
NZ530040A (en) 2005-11-25
BRPI0210085B8 (pt) 2021-07-20
NO20035211D0 (no) 2003-11-24
JP2004532863A (ja) 2004-10-28
WO2002096401A1 (en) 2002-12-05
HK1061652A1 (en) 2004-09-30
NO328805B1 (no) 2010-05-18
EP1397127B1 (en) 2007-03-21
AU2002318155B8 (en) 2008-05-15
CN1318026C (zh) 2007-05-30

Similar Documents

Publication Publication Date Title
MXPA03010705A (es) Formulaciones farmaceuticas solidas que comprenden modafinil.
GB0004128D0 (en) Novel compounds
WO2004024134A8 (en) Pharmaceutical formulations of modafinil
AP1770A (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their sythesis.
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
PL367682A1 (en) Dolastatin 10 derivatives
YU63703A (sh) 6-supstituisani pirido-pirimidini
MY128924A (en) Novel compounds
MXPA04003796A (es) Tioacetamidas sustituidas.
MY140081A (en) Pharmaceutical formulations of modafinil
DE60112330D1 (en) Pyrazolopyridinderivate
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
MXPA03010158A (es) Sulfonamidas.
SE0102716D0 (sv) Novel compounds
DE60201074D1 (en) Pyrazolopyridinderivate
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
MXPA04005151A (es) Compuestos terapeuticos.
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
SI1651596T1 (sl) Novi derivati ditiobis aminobutan sulfonatov in sestavki ki jih vsebujejo
DE60212130D1 (en) Carvedilolpolymorph
DE60214004D1 (en) Tricyclische epoxide
EP1444247A4 (en) NEW TIBOLON FORMULATIONS
AR033910A1 (es) Nuevas formulaciones farmaceuticas de moda-finil
MXPA03001440A (es) Compuestos de trioxepano novedosos.

Legal Events

Date Code Title Description
FG Grant or registration